plerixafor has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alitalo, K; Kim, I; Kim, KE; Kim, M; Koh, BI; Koh, GY; Koh, YJ; Nam, DH | 1 |
| Arra, C; Barbieri, A; Bryce, J; D'Alterio, C; Franco, R; Ieranò, C; Luciano, A; Palma, G; Polimeno, M; Portella, L; Rea, D; Riccio, A; Scala, S; Scognamiglio, G | 1 |
2 other study(ies) available for plerixafor and B16 Melanoma
| Article | Year |
|---|---|
CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.
Topics: AC133 Antigen; Animals; Antigens, CD; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Dacarbazine; Drug Resistance, Neoplasm; Endothelial Cells; Glycoproteins; Heterocyclic Compounds; Lung Neoplasms; Lymphatic Metastasis; Lymphatic Vessels; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptides; Receptors, CXCR4; Signal Transduction | 2010 |
Inhibition of stromal CXCR4 impairs development of lung metastases.
Topics: Animals; Antigens, Ly; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocytes; Heterocyclic Compounds; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Receptors, CXCR4; Stromal Cells | 2012 |